home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

Old Drug, New Target

  May, 10 2006 13:18
your information resource in human molecular genetics
Scientists have identified a new target for an old drug that has been used to treat tuberculosis for over 50 years. This finding, reported in the May 2006 issue of Nature Structural & Molecular Biology, should be useful for designing new antitubercular compounds.

Tuberculosis is a global health threat, and an estimated two million people die each year of the disease. The drug isoniazid is the first line of defense against the bacteria that cause the disease. It is processed by an enzyme in the microbe, and one of the resulting products interferes with the synthesis of the bacterial cell wall, thereby quickly killing the pathogen.

Blanchard and colleagues now find that isoniazid targets another process essential for the survival of the tubercular bacteria. They show that a different product from isoniazid processing inhibits an enzyme called DHFR, which is important for the synthesis of nucleic acid building blocks. The authors further demonstrate in detail how DHFR is inhibited by the isoniazid metabolite. These results may explain the emergence of some drug-resistant tubercular bacteria observed in the clinic and should provide a foundation for engineering new drugs for treating the disease.

Author contact:

John Blanchard (Albert Einstein College of Medicine, Bronx, NY, USA)
E-mail: blanchar@aecom.yu.edu

Abstract available online.

(C) Nature Structural & Molecular Biology press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.